Dose-seeking Study of Pembrolizumab Plus Vemurafenib and Cobimetinib Advanced Melanoma

Stopped Accrual to trial stopped due to high toxicity even at lowest dose of combination treatment. Patients on trial tolerating treatment at time of accrual closure still continued to receive treatment.

Conditions

• Melanoma

Interventions

• DRUG: Pembrolizumab
• DRUG: Vemurafenib
• DRUG: Cobimetinib

Sponsor

Yana Najjar

Collaborators

• [object Object]